Dyadic International (DYAI) Stock Price, Quote & News

Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products f...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 743 8333

Fax: 561 743 8343

Website: www.dyadic.com

Address:

1044 North U.S. Highway One, Suite 201, Jupiter, United States

Glopolon Aug. 24 at 5:35 PM

$DYAI https://www.youtube.com/watch?v=VWVN80XiPqs&t=2s

0 · Reply

FintechInvestmentGroup Aug. 23 at 11:29 AM

$DYAI Dyadic International Inc is facing biopharmaceutical technology adoption challenges

1 · Reply

ZacksSCR Aug. 15 at 1:33 PM

$DYAI: One Strain To Rule Them All https://buff.ly/mg6iFag

0 · Reply

d_risk Aug. 14 at 3:26 AM

$DYAI - DYADIC INTERNATIONAL INC - 10Q - Updated Risk Factors DYAI warns that failure to meet Nasdaq listing requirements could lead to delisting, pushing its stock to over-the-counter markets with no guarantee of eligibility or liquidity. #Biotechnology #DelistingRisk #MarketLiquidity #NasdaqCompliance #StockListingRisk 🟢 Added 🟠 Removed https://d-risk.ai/DYAI/10-Q/2025-08-13

1 · Reply

Glopolon Aug. 13 at 9:45 PM

$DYAI Joe H. anticipating cash generation by end of 2026. Cash spend should be equal or less in 2026.

1 · Reply

Glopolon Aug. 13 at 8:08 PM

$DYAI $13M cash, appox

0 · Reply

Glopolon Aug. 13 at 8:07 PM

$DYAI Fermbox delivery made, sharing revenue 50/50. Expects $750,000 milestones in Q3 2025.

0 · Reply

ybor2712 Aug. 12 at 3:25 PM

$DYAI R/S reverse split

0 · Reply

ybor2712 Aug. 7 at 7:14 PM

$DYAI rs

0 · Reply

MGeronimo Aug. 6 at 1:45 AM

$DYAI IN AT 1.02

0 · Reply

Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:01 PM EDT - 11 days ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Aug 5, 2025, 4:11 PM EDT - 19 days ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jul 31, 2025, 8:47 AM EDT - 25 days ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 31, 2025, 7:30 AM EDT - 25 days ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 30, 2025, 4:02 PM EDT - 25 days ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Jul 2, 2025, 4:00 PM EDT - 7 weeks ago

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Jun 2, 2025, 8:35 AM EDT - 3 months ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

May 14, 2025, 11:31 PM EDT - 3 months ago

Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript

May 1, 2025, 3:00 PM EDT - 4 months ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Apr 16, 2025, 2:00 PM EDT - 4 months ago

Dyadic to Present at World Vaccine Congress | Washington

Mar 26, 2025, 10:58 PM EDT - 5 months ago

Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:05 PM EDT - 5 months ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Mar 12, 2025, 4:00 PM EDT - 5 months ago

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

Mar 6, 2025, 8:30 AM EST - 6 months ago

Dyadic to Attend Multiple Industry Events in March

Jan 6, 2025, 8:30 AM EST - 8 months ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Nov 21, 2024, 8:30 AM EST - 9 months ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 16, 2024, 8:16 PM EST - 10 months ago

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:30 PM EST - 10 months ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 9, 2024, 8:00 AM EDT - 11 months ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Sep 23, 2024, 9:50 AM EDT - 11 months ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Aug 13, 2024, 11:05 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 4:00 PM EDT - 1 year ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

May 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Attend Industry Events in June

May 17, 2024, 10:15 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:00 PM EDT - 1 year ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry and Investor Events in May

Apr 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Mar 28, 2024, 10:22 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:00 PM EDT - 1 year ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Change in Board and Management Leadership Roles

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry Events in April

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 21, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 14, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 11, 2024, 9:57 AM EDT - 1 year ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend Industry Events in March

Feb 28, 2024, 8:30 AM EST - 1 year ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Feb 23, 2024, 2:00 AM EST - 1 year ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 13, 2024, 8:30 AM EST - 1 year ago

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Feb 6, 2024, 8:30 AM EST - 1 year ago

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Feb 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

Jan 22, 2024, 8:00 AM EST - 1 year ago

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

Jan 2, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

Nov 30, 2023, 8:30 AM EST - 1 year ago

Dyadic Attends Investor Events in December

Nov 29, 2023, 8:30 AM EST - 1 year ago

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Nov 20, 2023, 8:30 AM EST - 1 year ago

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Glopolon Aug. 24 at 5:35 PM

$DYAI https://www.youtube.com/watch?v=VWVN80XiPqs&t=2s

0 · Reply

FintechInvestmentGroup Aug. 23 at 11:29 AM

$DYAI Dyadic International Inc is facing biopharmaceutical technology adoption challenges

1 · Reply

ZacksSCR Aug. 15 at 1:33 PM

$DYAI: One Strain To Rule Them All https://buff.ly/mg6iFag

0 · Reply

d_risk Aug. 14 at 3:26 AM

1 · Reply

Glopolon Aug. 13 at 9:45 PM

$DYAI Joe H. anticipating cash generation by end of 2026. Cash spend should be equal or less in 2026.

1 · Reply

Glopolon Aug. 13 at 8:08 PM

$DYAI $13M cash, appox

0 · Reply

Glopolon Aug. 13 at 8:07 PM

$DYAI Fermbox delivery made, sharing revenue 50/50. Expects $750,000 milestones in Q3 2025.

0 · Reply

ybor2712 Aug. 12 at 3:25 PM

$DYAI R/S reverse split

0 · Reply

ybor2712 Aug. 7 at 7:14 PM

$DYAI rs

0 · Reply

MGeronimo Aug. 6 at 1:45 AM

$DYAI IN AT 1.02

0 · Reply

ybor2712 Aug. 5 at 8:19 PM

$DYAI Today would have been the deadline for compliance, but that wasn't the case. So are we moving on to R/S?

0 · Reply

ybor2712 Aug. 4 at 8:59 AM

$DYAI It would have been enough to stay until tomorrow and close above the dollar for compliance, but the conditions are not there. May God help us or else it will be a R/S and the money will go down the toilet.

0 · Reply

akts Aug. 1 at 1:13 AM

$DYAI Its a NEW DAY for DYAI. In this phase the company will be scratching for capital, diluting its share structure, and figuring out how to make their progress/announcements ever more sphinx-like. The "partners" and the "deals" in substance and timelines are not to be believed. This has been proven as the cash hoard has gone from $70MM to $5M? The BS is no longer coming from Mark E., but his new spokesman/sales guy. Proliant may be another JNJ/Indian/Bangladeshi/S.African/Israeli/Animal Health, etc. pipedream. Hope that's not the case, but I've been here 8+ years, through it all. BETTER FASTER CHEAPER and its not working for anyone? Wow....prove us wrong!!! For Mark E. to dilute his family's wealth is a truly frightening sign.

2 · Reply

DetectingRunners Jul. 31 at 9:33 PM

$DYAI 6mil shares

0 · Reply

OpenOutcrier Jul. 31 at 11:55 AM

$DYAI (-11.5% pre) Dyadic prices public offering of 6.05 million shares https://ooc.bz/l/72034

0 · Reply

ybor2712 Jul. 31 at 8:56 AM

$DYAI OPA

0 · Reply

stockanalysis_ Jul. 30 at 8:17 PM

After Hours Losers: $ALGN $DYAI $CFLT $PSIG $LUNG View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

ybor2712 Jul. 30 at 7:12 AM

$DYAI Who knows how many more days are left to avoid complications after the letter received from Nasdaq?

1 · Reply

SPACEDAD Jul. 24 at 9:52 PM

$DYAI seems like this might pump. Watching closely for if it goes back around the 1.20-1.30 to see if there’s some life in it.

0 · Reply

akts Jul. 24 at 7:42 PM

$DYAI Something shady going on. Enormous volume just as they get their NASDAQ listing <$1 notice. Then a updated presentation that confirms no Proliant business probably not until 2026, and reference to 12-36 month timelines on basically their revenue(s) streams. Maybe someone threw them a financial lifeline to keep them afloat. They will run out of money within the next 9 months....skating on very thin ice at this point.

1 · Reply

SmartMoneyTradez Jul. 24 at 3:51 PM

$DYAI Still going up. $OKLO $TSLA $HCTI

1 · Reply

Tarrytabby Jul. 24 at 6:21 AM

$DYAI Investor Presentation JULY 2025 https://dyadic.com/investors/presentations/

0 · Reply

Market Cap	30.76M
Revenue (ttm)	3.50M
Net Income (ttm)	-5.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-166.00%
Debt to Equity Ratio	0.00

Volume	253,900
Avg Vol	144,516
Day's Range	N/A - N/A
Shares Out	36.19M
Stochastic %K	74%
Beta	0.89
Analysts	Strong Buy
Price Target	$9.00